Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
Drug Saf
    September 2021
  1. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
    Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Drug Saf. 2021;44:987-998.
    >> Share

  2. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
    NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
    Drug Saf. 2021;44:929-938.
    >> Share

    June 2021
  3. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
    Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
    Drug Saf. 2021;44:635-644.
    >> Share

    April 2021
  4. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    >> Share

  5. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
    French Pharmacovigilance Public System and COVID-19 Pandemic.
    Drug Saf. 2021;44:405-408.
    >> Share

    February 2021
  6. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
    Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
    Drug Saf. 2021;44:255-257.
    >> Share

    January 2021
  7. BEYZAROV E, Chen Y, Julg R, Naim K, et al
    Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Drug Saf. 2021;44:95-105.
    >> Share

  8. SHAKIR S, Lane S, Davies M
    How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Drug Saf. 2021;44:1-5.
    >> Share

    December 2020
  9. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
    Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Drug Saf. 2020;43:1315-1322.
    >> Share

  10. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    >> Share

  11. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    >> Share

  12. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    >> Share

    August 2020
  13. OSBORNE V, Davies M, Lane S, Evans A, et al
    Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:809-821.
    >> Share

  14. SULTANA J, Cutroneo PM, Crisafulli S, Puglisi G, et al
    Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
    Drug Saf. 2020;43:691-698.
    >> Share

  15. TUCCORI M, Convertino I, Ferraro S, Cappello E, et al
    The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
    Drug Saf. 2020;43:699-709.
    >> Share

    July 2020
  16. MOORE N, Carleton B, Blin P, Bosco-Levy P, et al
    Does Ibuprofen Worsen COVID-19?
    Drug Saf. 2020;43:611-614.
    >> Share

  17. OLRY A, Meunier L, Delire B, Larrey D, et al
    Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.
    Drug Saf. 2020;43:615-617.
    >> Share

  18. MONTASTRUC JL, Toutain PL
    A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
    Drug Saf. 2020;43:657-660.
    >> Share

  19. DAVIES M, Osborne V, Lane S, Roy D, et al
    Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:645-656.
    >> Share

    June 2020
  20. CHANDLER RE, McCarthy D, Delumeau JC, Harrison-Woolrych M, et al
    The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic.
    Drug Saf. 2020;43:511-512.
    >> Share

  21. TRIFIRO G, Crisafulli S, Ando G, Racagni G, et al
    Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
    Drug Saf. 2020;43:507-509.
    >> Share

    May 2020
  22. MOORE N
    Chloroquine for COVID-19 Infection.
    Drug Saf. 2020;43:393-394.
    >> Share

    December 2019
  23. DOS SANTOS G, Nguyen BY, Damaso S, Godderis L, et al
    Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Drug Saf. 2019 Dec 28. pii: 10.1007/s40264-019-00893.
    >> Share

    October 2017
  24. NIGWEKAR PV, Kumar A, Padbidri VV, Choudhury A, et al
    Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.
    Drug Saf. 2017 Oct 12. doi: 10.1007/s40264-017-0605.
    >> Share

    April 2017
  25. DOS SANTOS G, Seifert HA, Bauchau V, Shinde V, et al
    Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt.
    Drug Saf. 2017 Apr 17. doi: 10.1007/s40264-017-0532.
    >> Share

    December 2016
  26. MORO P, Baumblatt J, Lewis P, Cragan J, et al
    Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
    Drug Saf. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016